PURPOSE: Image-guided adaptive brachytherapy (IGABT) is currently state of the art in the comprehensive treatment of patients with cervical cancer. Here, we report mature clinical data regarding IGABT of cervical cancer in a large patient sample, examining clinical outcomes, manifestations of late toxicities, and dosimetric findings. METHODS: Between May 2012 and October 2020, we performed a total of 544 uterovaginal IGABT applications in 131 consecutive patients with biopsy-proven cervical carcinoma not suitable for surgery. The median duration of follow-up was 43 months. RESULTS: The estimated 3‑, 4‑, and 5‑year LC rates were 88.3% (95% confidence interval [CI] 81.1-95.5), 86.9% (95% CI 78.5-95.3), and 85.5% (95% CI 76-95%), respectively. The 3‑, 4‑, and 5‑year OS estimates were 72.66% (95% CI 63.64-81.69%), 68.9% (95% CI 59.15-78.66%), and 63.96% (95% CI 52.94-74.97%), respectively. Patients who received ≥ 5 cycles of chemotherapy had statistically significantly better 3‑year recurrence-free survival (RFS) compared to patients who completed <5 cycles (79.07% [95% CI 60.81-97.34] vs. 58.10% [95% CI 47.22-68.98]; p = 0.0185). We recorded manifestations of genitourinary and gastrointestinal toxicity grade ≥3 in 6.9% and 5.3%, respectively. CONCLUSION: Our mature long-term data on the treatment patients with locally advanced cervical cancer show that excellent treatment outcomes can be achieved with MRI-based IGABT, as well as acceptable late morbidity.

Biomedical Center Charles University Prague Faculty of Medicine in Pilsen alej Svobody 76 323 00 Pilsen Czech Republic

Department of Imaging Methods Charles University Prague Faculty of Medicine and University Hospital in Pilsen alej Svobody 80 304 60 Pilsen Czech Republic

Department of Oncology and Radiotherapy Charles University Prague Faculty of Medicine and University Hospital in Pilsen alej Svobody 80 304 60 Pilsen Czech Republic

Zobrazit více v PubMed

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660 PubMed

Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration (2008) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 26(35):5802–5812 PMC

Viswanathan AN, Thomadsen B, American Brachytherapy Society Cervical Cancer Recommendations Committee, American Brachytherapy Society (2012) American brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy 11(1):33–46 PubMed

Green JA, Kirwan JM, Tierney JF et al (2001) Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358(9284):781–786 PubMed

Shin KH, Kim TH, Cho JK et al (2006) CT-guided intracavitary radiotherapy for cervical cancer: comparison of conventional point A plan with clinical target volume-based three-dimensional plan using dose-volume parameters. Int J Radiat Oncol Biol Phys 64(1):197–204 PubMed

Haie-Meder C, Pötter R, Van Limbergen E et al (2005) Gynaecological (GYN) GEC-ESTRO working group. Recommendations from gynaecological (GYN) GEC-ESTRO working group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 74(3):235–245 PubMed

Pötter R, Haie-Meder C, Van Limbergen E, GEC ESTRO Working Group et al (2006) Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 78(1):67–77 PubMed

Fields EC, Hazell S, Morcos M et al (2020) Image-guided gynecologic brachytherapy for cervical cancer. Semin Radiat Oncol 30(1):16–28 PubMed

Pötter R, Dimopoulos J, Bachtiary B et al (2006) 3D conformal HDR-brachy- and external beam therapy plus simultaneous cisplatin for high-risk cervical cancer: clinical experience with 3 year follow-up. Radiother Oncol 79(1):80–86 PubMed

Pötter R, Dimopoulos J, Georg P et al (2007) Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol 83(2):148–155 PubMed

Dimopoulos JC, Lang S, Kirisits C et al (2009) Dose-volume histogram parameters and local tumor control in magnetic resonance image-guided cervical cancer brachytherapy. Int J Radiat Oncol Biol Phys 75(1):56–63 PubMed

Vojtíšek R, Sukovská E, Baxa J et al (2019) Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer : institutional experiences. Strahlenther Onkol 195(11):972–981 PubMed

Bhatla N, Berek JS, Cuello Fredes M et al (2019) Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 145(1):129–135 PubMed

Viswanathan AN, Beriwal S, De Los Santos JF, American Brachytherapy Society et al (2012) American brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy 11(1):47–52 PubMed PMC

Lang S, Kirisits C, Dimopoulos J et al (2007) Treatment planning for MRI assisted brachytherapy of gynecologic malignancies based on total dose constraints. Int J Radiat Oncol Biol Phys 69(2):619–627 PubMed

National Cancer Institute (2010) Common terminology criteria for adverse events (CTCAE) (Version 5.0)

Wachter-Gerstner N, Wachter S, Reinstadler E et al (2003) The impact of sectional imaging on dose escalation in endocavitary HDR-brachytherapy of cervical cancer: results of a prospective comparative trial. Radiother Oncol 68(1):51–59 PubMed

Pötter R, Georg P, Dimopoulos JC et al (2011) Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol 100(1):116–123 PubMed PMC

Schernberg A, Bockel S, Annede P et al (2018) Tumor shrinkage during chemoradiation in locally advanced cervical cancer patients: prognostic significance, and impact for image-guided adaptive brachytherapy. Int J Radiat Oncol Biol Phys 102(2):362–372 PubMed

Lindegaard JC, Fokdal LU, Nielsen SK et al (2013) MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a nordic perspective. Acta Oncol 52(7):1510–1519 PubMed

Mazeron R, Gilmore J, Dumas I et al (2013) Adaptive 3D image-guided brachytherapy: a strong argument in the debate on systematic radical hysterectomy for locally advanced cervical cancer. Oncologist 18(4):415–422 PubMed PMC

Nomden CN, de Leeuw AA, Roesink JM et al (2013) Clinical outcome and dosimetric parameters of chemo-radiation including MRI guided adaptive brachytherapy with tandem-ovoid applicators for cervical cancer patients: a single institution experience. Radiother Oncol 107(1):69–74 PubMed

Gill BS, Kim H, Houser CJ et al (2015) MRI-guided high-dose-rate intracavitary brachytherapy for treatment of cervical cancer: the University of Pittsburgh experience. Int J Radiat Oncol Biol Phys 91(3):540–547 PubMed

Mahantshetty U, Krishnatry R, Hande V et al (2017) Magnetic resonance image guided adaptive brachytherapy in locally advanced cervical cancer: an experience from a tertiary cancer center in a low and middle income countries setting. Int J Radiat Oncol Biol Phys 99(3):608–617 PubMed

Vojtíšek R, Sukovská E, Baxa J et al (2019) Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer: institutional experiences. Strahlenther Onkol 195(11):972–981 PubMed

Grueneisen J, Schaarschmidt BM, Heubner M et al (2015) Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results. Eur J Nucl Med Mol Imaging 42(12):1814–1824 PubMed

Nomden CN, Pötter R, de Leeuw AAC, EMBRACE Collaborative Group et al (2019) Nodal failure after chemo-radiation and MRI guided brachytherapy in cervical cancer: patterns of failure in the EMBRACE study cohort. Radiother Oncol 134:185–190 PubMed

Sturdza A, Pötter R, Fokdal LU et al (2016) Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in retroEMBRACE, a multicenter cohort study. Radiother Oncol 120(3):428–433 PubMed

Liu FY, Su TP, Wang CC et al (2018) Roles of posttherapy PubMed

Scher N, Castelli J, Depeursinge A et al (2018) ( PubMed

Mazeron R, Fokdal LU, Kirchheiner K et al (2016) EMBRACE collaborative group. Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: results from the prospective multicenter EMBRACE study. Radiother Oncol 120(3):412–419 PubMed

Bockel S, Escande A, Dumas I et al (2019) Total reference air kerma is associated with late bowel morbidity in locally advanced cervical cancer patients treated with image-guided adaptive brachytherapy. J Clin Med 8(1):125 PMC

ClinicalTrials.gov (2018) Image guided IMRT, radiochemotherapy and MRI-based IGABT in locally advanced cervical cancer (EMBRACEII). https://clinicaltrials.gov/ct2/show/NCT03617133 . Accessed 01 September 2021

Fortin I, Tanderup K, Haie-Meder C et al (2016) Image guided brachytherapy in cervical cancer: a comparison between intracavitary and combined intracavitary/interstitial brachytherapy in regard to doses to HR CTV, OARs and late morbidity—early results from the EMBRACE study in 999 patients. Brachytherapy 15:S21

Manea E, Escande A, Bockel S et al (2018) Risk of late urinary complications following image guided adaptive brachytherapy for locally advanced cervical cancer: refining bladder dose-volume parameters. Int J Radiat Oncol Biol Phys 101(2):411–420 PubMed

Vojtíšek R, Baxa J, Kovářová P et al (2021) Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy. Strahlenther Onkol 197(6):494–504 PubMed

Mileshkin LR, Moore KN, Barnes E et al (2021) Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: the randomized phase III OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274). J Clin Oncol. https://doi.org/10.1200/JCO.2021.39.15

ClinicalTrials.gov (2012) Induction chemotherapy plus chemoradiation as first line treatment for locally advanced cervical cancer (INTERLACE). https://clinicaltrials.gov/ct2/show/NCT01566240 . Accessed 01 September 2021

ClinicalTrials.gov (2018) Trial assessing the inhibitor of programmed cell death ligand 1 (PD-L1) immune checkpoint atezolizumab (ATEZOLACC). https://clinicaltrials.gov/ct2/show/NCT03612791 . Accessed 01 September 2021

Association of long-term treatment outcomes with changes in PET/MRI characteristics and the type of early treatment response during concurrent radiochemotherapy in patients with locally advanced cervical cancer